Emerging systemic fungal infections

Clinics in Dermatology

Volumn 30, Issue 6, 2012, Pages 633-650

  Galimberti, Ricardo ^a   Torre, Ana Clara ^a   Baztán, María Carolina ^a   Rodriguez Chiappetta, Florencia ^a  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; BETA GLUCAN; CASPOFUNGIN; CICLOPIROXOLAMINE; CLOTRIMAZOLE; CORTICOSTEROID; ECHINOCANDIN; ECONAZOLE; FLUCONAZOLE; FLUCYTOSINE; GALACTOMANNAN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NATAMYCIN; POLYENE; POSACONAZOLE; TERBINAFINE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ALLERGIC DISEASE; ASPERGILLOMA; ASPERGILLOSIS; ASPERGILLUS; BONE INFECTION; CLINICAL FEATURE; DERMATOMYCOSIS; DERMATOPHYTOSIS; DIAGNOSTIC IMAGING; DRUG ANTAGONISM; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG PULSE THERAPY; FEBRILE NEUTROPENIA; FOREIGN BODY; FUNGAL SINUSITIS; FUNGUS CULTURE; FUSARIOSIS; FUSARIUM OXYSPORUM; FUSARIUM SOLANI; HISTOPATHOLOGY; HUMAN; INCIDENCE; INFECTIOUS ARTHRITIS; INVASIVE ASPERGILLOSIS; KERATOMYCOSIS; LOADING DRUG DOSE; LUNG MYCOSIS; MICROBIOLOGY; MORTALITY; NEUTROPENIA; NONHUMAN; NOTE; ONYCHOMYCOSIS; OTOMYCOSIS; PATHOGENESIS; PENICILLIOSIS; PENICILLIUM MARNEFFEI; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SCREENING TEST; SURVIVAL RATE; SYSTEMIC MYCOSIS; UNSPECIFIED SIDE EFFECT;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; COMMUNICABLE DISEASES, EMERGING; FUSARIOSIS; FUSARIUM; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; PENICILLIUM;

EID: 84867619651     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2012.01.011     Document Type: Note

References (88)

1. Galimberti R., Kowalczuk A.M., Hidalgo Parra I., Gonzalez Ramos M., Flores V. Cutaneous aspergillosis: a report of six cases. Br J Dermatol 1998, 139:522-526.
2. Morgan J., Wannemuehler K.A., Marr K.A., et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005, 43:49.
3. Marr K., Carter R., Crippa F., et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002, 34:909.
4. Maschmeyer G., Haas A., Cornely O.A. Invasive aspergillosis. Epidemiology, diagnosis and management in immunocompromised patients. Drugs 2007, 67:1567-1601.
5. Marr K.A., Patterson T., Denning D. Aspergillosis pathogenesis, clinical manifestations and therapy. Infect Dis Clin 2002, 16:875-894.
6. Segal B.H. Aspergillosis. N Engl J Med 2009, 360:1870-1884.
7. Del Bono V., Mikulska M., Viscoli C. Invasive aspergilosis: diagnosis, prophylaxis and treatment. Curr Opin Hematol 2008, 15:586-593.
8. Arnold T.M., Sears C.R., Hage C.A. Invasive fungal infections in the era of biologics. Clin Chest Med 2009, 30:279-286.
9. Moreno G., Arenas R. Other fungi causing onychomycosis. Clin Dermatol 2010, 28:160-163.
10. Arechavala A., Bonvehi P., Negroni R. Perfil de las onicomicosis basado en 2106 exámenes micológicos. Dermatol Arg 2006, 12:205-211.
11. Negroni R., Arechavala A., Bonheví P. Hongos miceliales no dermatofitos em onicodistrofias. Experiencia de um centro médico privado de Buenos Aires. Dermatol Arg 2008, 14:118-123.
12. Galimberti R., Flores V., Raimondi A., Kowalczuk A.M. Nodular secondary cutaneous aspergillosis. Micologia dermatologica 1988, 2:13-17.
13. Zloty P. Diagnosis and management of fungal keratitis. Focal Points: Clinical Modules for Ophthalmologists 2002, 20:1-13.
14. Sedo S., Iribarne Y., Fossas M., Vendrell C., Ortiz F. Queratitis fúngica. Annals d'Oftalmologia 2003, 11:168-175.
15. del Palacio A., Cuétara M.S., Pontón J. El diagnóstico de laboratorio de la aspergilosis invasora. Rev Iberoam Micol 2003, 20:90-98.
16. Guarro J., Gené J., Stchigel A.M. Developments in fungal taxonomy. Clin Microbiol Rev 1999, 12:454-500.
17. Abarca M.L. Taxonomía e identificación de especies implicadas en la aspergilosis nosocomial. Rev Iberoam Micol 2000, 17:79-84.
18. Hayden R.T., Isotalo P.A., Parrett T., et al. In situ hybridization for the differentiation of Aspergillus, Fusarium, and Pseudallescheria species in tissue section. Diagn Mol Pathol 2003, 12:21-26.
19. Odabasi Z., Mattiuzzi G., Estey E., et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004, 39:199-205.
20. Aubry A., Porcher R., Bottero J., et al. Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders. J Clin Microbiol 2006, 44:389.
21. Cornely O.A., Maertens J., Winston D.J., et al. Posaconazole vs. fluconazole vs. itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007, 356:348-359.
22. De Pauw B.E., Donnelly J.P. Prophylaxis and aspergilosis. Has the principle been proven?. N Engl J Med 2007, 356:409-411.
23. Verweij P.E., Mellado E., Melchers W.J.G. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007, 256:1481-1483.
24. Warris A., Weemaes C.M., Verweij P.E. Multidrug resistance in Aspergillus fumigatus. N Engl J Med 2002, 347:2173-2174.
25. Chamilos G., Kontoyiannis D.P. The rationale of combination antifungal therapy in severely immunocompromised patients: empiricism versus evidence-based medicine. Curr Opin Infect Dis 2006, 19:380-385.
26. Herbretch R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-415.
27. Nelson P.E., Dignani M.C., Anaissie E.J. Taxonomy, biology and clinical aspects of Fusarium species. Clin Microbiol Rev 1994, 7:479-504.
28. Dignani M.C., Anaissie E. Human fusariosis. Clin Microbiol Infect 2004, 10:67-75.
29. St-Germain G., Summerbell R.C. Fusarium. Identifying filamentous fungi 1996, 122-123. Blackwell Science, Belmont. G. St-Germain, R.C. Summerbell (Eds.).
30. Nucci M., Anaissie E. Fusarium infections in immunocompromised patients. Clin Microb Rev 2007, 20:695-704.
31. Baran R., Tosti A., Piraccini B.N. Uncommon clinical patterns of Fusarium nail infection: report of three cases. Br J Dermatol 1997, 136:424-427.
32. Mallo-García S., Coto-Segura P., Santos-Juanes-Jiménez J. Proximal white subungual onycomycosis due to Fusarium species. Actas Dermatosifiliogr 2008, 99:142-143.
33. Nadler J.P. Disseminated fusarial infection. Rev Infect Dis 1990, 12:70-73.
34. Nucci M., Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002, 35:909-920.
35. Hay R.J. Fusarium infections of the skin. Curr Opin Infect Dis 2007, 20:115-117.
36. Monzón A., Rodríguez Tudela J,L. Infecciones causadas por el género Fusarium. Servicio de Micología 2000, Centro Nacional de Microbiología Instituto de Salud Carlos III, Majadahonda, Spain.
37. Negroni R., Martino O., Robles A.M., Orduna T. Ulcera cutánea provocada por hongos del género fusarium. Revista da Sociedad Brasileira de Medicina Tropical 1997, 30:323-328.
38. Dignani M.C., Kiwan E.N., Anaissie E.J. Hyalohyphomycoses. Clinical mycology 2003, 309-324. Churchill Livingston, Philadelphia. E. Anaissie, M.R. McGinnis, M.A. Pfaller (Eds.).
39. Arenas R. Hialohifomicosis, y feohifomicosis. Micología médica ilustrada 2003, 315. McGraw-Hill, Mexico. R. Arenas (Ed.).
40. Booth C. The genus Fusarium. Kew, UK: Commonwealth Mycological Institute; 1997. p. 237.
41. Anaissie E., Kantarjian H., Ro J., Rolston K., et al. The emerging role of Fusarium infections in patients with cancer. Medicine 1988, 67:77-83.
42. Procop G.W., Roberts G.D. Emerging fungal diseases: the importance of the host. Clin Lab Med 2004, 24:691-719.
43. Sampathkumar P., Paya C.V. Fusarium infection after solid-organ transplantation. Clin Infectious Dis 2001, 32:1237-1240.
44. Boutati E.I., Anaissie E.J. Fusarium, a significant emerging pathogen in patients with haematologic malignancy: ten years' experience at a center and implications for management. Blood 1997, 90:999-1008.
45. Jensen T.G. Fusarium fungaemia in immunocompromised patients. Clin Microbiol Infect 2004, 10:499-501.
46. Musa M.O., Eisa A.l. The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution over 10 years. Br J Haematol 2000, 108:544-548.
47. Nucci M., Anaissie E.J., Queiroz-Telles F., et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003, 98:315-319.
48. Nucci M., Marr K.A., Queiroz-Telles F., et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004, 38:1237-1242.
49. Kuriakose T. Intracameral amphotericin B injection in the management of deep keratomycosis. Cornea 2002, 7:653-656.
50. Bibashi E., Kokolina E., Sigler L., et al. Three cases of uncommon fungal peritonitis in patients undergoing peritoneal dialysis. Perit Dial Int 2002, 22:523-525.
51. Young J.B., Ahmed-Jushuf I.H., Brownjohn A.M., et al. Opportunistic peritonitis in continuous ambulatory peritoneal dialysis. Clin Nephrol 1984, 22:268-269.
52. Velasco E., Martins C.A., Nucci M. Successful treatment of catheter-related fusarial infection in immunocompromised children. Eur J Clin Microbiol Infect Dis 1995, 14:697-699.
53. Neuburger S., Massenkeil G., Seibold M., et al. Successful salvage treatment of disseminated cutaneous fusariosis with liposomal amphotericin B and terbinafine after allogeneic stem cell transplantation. Transpl Infect Dis 2008, 104:290-293.
54. Hennequin C., Lavarde V., Poirot J.L., et al. Invasive Fusarium infections: a retrospective survey of 31 cases. The French 'Groupe d'Etudes des Mycoses Opportunistes' GEMO. J Med Vet Mycol 1997, 35:107-114.
55. Anaissie E.J., Kuchar R.T., Rex J.H., et al. Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system, a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis 2001, 33:1871-1878.
56. Anaissie E.J., Stratton S.L., Dignani M.C., et al. Cleaning patient shower facilities: a novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds. Clin Infect Dis 2002, 35:86-88.
57. Allevato M., Negroni R., Galimberti R. Antifúngicos Ayer, hoy y mañana. Act Terap Dermatol 2007, 30:8.
58. Sociedad Argentina De Infectología Guías De Consenso En El Manejo Del Paciente Neutropénico. Buenos Aires: Comisión De Infecciones En El Paciente Neoplásico y Transplantado 1996, 8.
59. Stanzani M., Tumietto F., Vianelli N., Baccarani M. Update on the treatment of disseminated fusariosis: focus on voriconazole. Therapeutics and clinical risk management 2007, 3:1165-1173.
60. Negroni R. Tratamiento de las onicomicosis. Revista de Patología Tropical 2008, 37:89-109.
61. Anaissie E., Paetznick V., Proffitt R., et al. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin. B Eur J Clin Microbiol Infect Dis 1991, 10:665-668.
62. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003, 20:121-136.
63. Espinel-Ingroff A., Chaturvedi V., Fothergill A., Rinaldi M.G. Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J Clin Microbiol 2002, 40:3776-3781.
64. Arikan S., Lozano-Chiu M., Paetznick V., et al. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol 1999, 37:3946-3951.
65. Raad I.I., Hachem R.Y., Herbretch R., et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. CID 2006, 42:1398-1403.
66. Gabardi S., Kubiak D.W., Chandraker A.K., Stefan G. Invasive fungal infections and antifungal therapies in solid organ transplant recipients. European Society for Organ Transplantation 2007, 993-1015.
67. Ho D.Y., Lee J.D., Rosso F., Montoya J.G. Treating disseminated fusariosis: amphotericin B, voriconazole or both?. Mycosis 2007, 50:227-231.
68. Tawara S., Ikeda F., Maki K., et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000, 44:57-62.
69. Dignani M.C., Anaissie E.J., Hester J.P., et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia 1997, 11:1621-1630.
70. Hennequin C., Benkerrou M., Gaillard J.L., et al. Role of granulocyte colony-stimulating factor in the management of infection with Fusarium oxysporum in a neutropenic child. Clin Infect Dis 1994, 18:490-491.
71. Lyratzopoulos G., Ellis M., Nerringer R., Denning D. Invasive infection due to Penicillium species other than P. marneffei. J Infect 2002, 45:184-207.
72. Vanittanakom N., Cooper C.R., Fisher M.C., Sirisanthana T. Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clin Microbiol Rev 2006, 19:95-110.
73. Ustianowski A.P., Sieu T.P.M., Day J.N. Penicillium marneffei infection in HIV. Infect Dis 2008, 21:31-36.
74. Drouhet E. Penicillosis due to Penicillium marneffei: a new emerging systemic mycosis in AIDS patients travelling or living in southeast-Asia. Review of 44 cases reported in HIV infected patients during the last 5 years compared to 44 cases of non AIDS patients reported over 20 years. J Mycol Med 1993, 4:195-224.
75. Imwidthaya P. Update of penicillosis marneffei in Thailand. Review article. Mycopathologia 1994, 127:135-137.
76. Hein T.V., Loc P.P., Hoa N.T.T., et al. First cases of disseminated Penicillosis marneffei infection among patients with adquired immunodeficiency syndrome in Vietnam. Clin Infect Dis 2001, 32:674-678.
77. Mohri S., Yoshikawa K., Sagara H., Nakajima H. A case of Penicillium marneffei infection in an AIDS patient the first case in Japan. Nihon Ishinkin Gakkai Zasshi 2000, 41:23-26.
78. Nelson K.E., Sirisanthana T. Disseminated Penicillium marneffei infection in a patient with AIDS. N Engl J Med 2001, 344:1763.
79. Singh P.N., Ranjana K., Singh Y.I., et al. Indigenous disseminated Penicillium marneffei infection in the State of Manipur, India: report of 4 autochthoctonous cases. J Clin Microbiol 1999, 37:2699-2702.
80. Sirisanthana T., Supparatpinyo K., Chariyalertsak S., et al. Clinical presentation of 74 HIV-infected patients with disseminated Penicillium marneffei infection. J Infect Dis 1998, 15:65-68.
81. Sirisanthana T. Penicillium marneffei infection in patients with AIDS. Emerging Infect Dis 2001, 7:561.
82. Viviani M.A., Tortorano A.M. Penicillium marneffei. Topley & Wilson's Microbiology and Microbial Infections 1998, 409-419. Hodder Arnold Publications, London. 9th ed. L. Ajello, R. Hay (Eds.).
83. Sirisanthana T., Supparatpinyo K. Epidemiology and management of penicillosis in human immunodeficiency virus-infected patients. Intern J Infect Dis 1998, 3:48-53.
84. Bateman A.C., Jones G.R., O'Connell S., Clark F., Phimmerigde M. Massive hepatosplenomegaly caused by Penicillium marneffei associated with human immunodeficiency virus infection in a Thai patient. J Clin Pathol 2002, 55:143-144.
85. Antinori S., Gianelli E., Bonaccorso C., et al. Disseminated Penicillium marneffei infection in an HIV-positive Italian patient and a review of cases reported outside endemic regions. J Travel Med 2006, 13:181-188.
86. Marques S.A., Robles A.M., Tortorano A.M., Tuculet M.A., Negroni R., Mendes R.P. Mycoses associated with AIDS in the Third World. Med Mycol 2000, 38:269-279.
87. Kudeken N., Kawakami K., Saito A. Mechanisms of the "in vitro" fungicidal effects of human neutrophils against Penicillium marneffei induced by granulcyte-macrophage colony-stimulating factor (GM-CSF). Clin Exp Immunol 2000, 119:472-478.
88. Ching H.C., Hsieh C.M.Y., Min S., Hwi S.W., Fu H.C., Chwen C.S. Discontinuation of secondary prophylaxis for penicillosis marnefei in AIDS patients responding to highly active antiretroviral therapy. AIDS 2002, 16:672-673.